Eradication of methicllin-resistant staphylococcus aureus carriage: A systematic review

Clinical Infectious Diseases

Volumn 48, Issue 7, 2009, Pages 922-930

  Ammerlaan, Heidi S M ^a,f   Kluytmans, Jan A J W ^b,c   Wertheim, Heiman F L ^d,e   Nouwen, Jan L ^d   Bonten, Marc J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c AMPHIA HOSPITAL   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^f Bach Mai Hospital ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; CHLORHEXIDINE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FUSIDIC ACID; JOSAMYCIN; MACROLIDE; MINOCYCLINE; NEOMYCIN; PLACEBO; PSEUDOMONIC ACID; RIFAMPICIN; ROSARAMICIN; TEA TREE OIL; TETRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT;

CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; DRUG TREATMENT FAILURE; HUMAN; MEDICAL LITERATURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; DRUG EFFECT; HETEROZYGOTE; MICROBIOLOGY; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CARRIER STATE; CLINICAL TRIALS AS TOPIC; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 63649144097     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597291     Document Type: Review

References (41)

1. Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005;5:751-62.
2. European Antimicrobial Resistance Surveillance System. EARSS annual report 2005: ongoing surveillance of S. pneumoniae, S. aureus, E. coli, E. faecium, E. faecalis. Bilthoven, The Netherlands: Rijksinstituut voor Volksgezondheid en Milieu, 2006.
3. Tiemersma EW, Bronzwaer SL, Lyytikainen O, et al. Methicillin-resis- tant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 2004;10:1627-34.
4. National Nosocomial Infections Surveillance (NNIS) System Report: data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
5. Hsueh PR, Chen ML, Sun CC, et al. Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. Emerg Infect Dis 2002;8:63-8.
6. Sanford MD, Widmer AF, Bale MJ, Jones RN, Wenzel RP. Efficient detection and long-term persistence of the carriage of methicillin-re- sistant Staphylococcus aureus. Clin Infect Dis 1994;19:1123-8.
7. Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis 2003;37:933-8.
8. Loeb M, Main C, Walker-Dilks C, Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 2003;CD003340.
9. Loveday HP, Pellowe CM, Jones SR, Pratt RJ. A systematic review of the evidence for interventions for the prevention and control of meth- icillin-resistant Staphylococcus aureus (1996-2004): report to the Joint MRSA Working Party (Subgroup A). J Hosp Infect 2006;63(Suppl 1): S45-70.
10. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24:362-86.
11. Coia JE, Duckworth GJ, Edwards DI, et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 2006;63(Suppl l):Sl-44.
12. Gemmell CG, Edwards DI, Praise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resis- tant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57:589-608.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
14. Wilson SZ, Martin RR, Putman M. In vivo effects of josamycin, erythromycin, and placebo therapy on nasal carriage of Staphylococcus aureus. Antimicrob Agents Chemother 1977;11:407-10.
15. Wilson SZ, Martin RR, Putman M, Greenberg SB, Wallace RJ Jr, Jemsek JG. Quantitative nasal cultures from carriers of Staphylococcus aureus; effects of oral therapy with erythromycin, rosamicin, and placebo. Antimicrob Agents Chemother 1979;15:379-83.
16. McAnally TP, Lewis MR, Brown DR. Effect of rifampin and bacitracin on nasal carriers of Staphylococcus aureus. Antimicrob Agents Chemother 1984; 25:422-6.
17. Casewell MW, Hill RL. Elimination of nasal carriage of Staphylococcus aureus with mupirocin ("pseudomonic acid"): a controlled trial. J Antimicrob Chemother 1986; 17:365-72.
18. Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis: efficacy of antibiotic prophylaxis. N Engl J Med 1986;315:91-6.
19. Bulanda M, Gruszka M, Heczko B. Effect of mupirocin on nasal carriage of Staphylococcus aureus. J Hosp Infect 1989;14:117-24.
20. Peterson LR, Quick JN, Jensen B, et al. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureusiso- lates: resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S. aureus colonization. Arch Intern Med 1990; 150: 2151-5.
21. Doebbeling BN, Breneman DL, Neu HC, et al. Elimination of Staphylococcus aureus nasal carriage in health care workers: analysis of six clinical trials with calcium mupirocin ointment. The Mupirocin Collaborative Study Group. Clin Infect Dis 1993; 17:466-74.
22. Leigh DA, Joy G. Treatment of familial staphylococcal infection: comparison of mupirocin nasal ointment and chlorhexidine/neomycin (Naseptin) cream in eradication of nasal carriage. J Antimicrob Chemother 1993;31:909-17.
23. Walsh TJ, Standiford HC, Reboli AC, et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 1993;37:1334-42.
24. Muder RR, Boldin M, Brennen C, et al. A controlled trial of rifampicin, minocycline, and rifampicin plus minocycline for eradication of methicillin-resistant Staphylococcus aureus in long-term care patients. J Antimicrob Chemother 1994;34:189-90.
25. Doebbeling BN, Reagan DR, Pfaller MA, Houston AK, Hollis RJ, Wen- zel RP. Long-term efficacy of intranasal mupirocin ointment: a prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med 1994;154:1505- 8.
26. Fernandez C, Gaspar C, Torrellas A, et al. A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J Antimicrob Chemother 1995; 35:399-408.
27. Parras F, Guerrero MC, Bouza E, et al. Comparative study of mupirocin and oral co-trimoxazole plus topical f'usidic acid in eradication of nasal carriage ot methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995;39:175-9.
28. Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999;43:1412-6.
29. Martin JN, Perdreau-Remington F, Kartalija M, et al. A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect Dis 1999; 180:896-9.
30. Soto NE, Vaghjimal A, Stahl-Avicolli A, Protic IR, Lutwick LI, Chapnick EK. Bacitracin versus mupirocin for Staphylococcus aureus nasal colonization. Infect Control Hosp Epidemiol 1999;20:351-3.
31. Chang SC, Hsieh SM, Chen ML, Sheng WH, Chen YC. Oral f'usidic acid fails to eradicate methicillin-resistant Staphylococcus aureus colonization and results in emergence of fusidic acid-resistant strains. Diagn Microbiol Infect Dis 2000;36:131-6.
32. Mody L, Kauffman CA, McNeil SA, Galecki AT, Bradley SF. Mupirocin- based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003;37:1467-74.
33. Berg HF, Tjhie JH, Scheffer GJ, et al. Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. Antimicrob Agents Chemother 2004;48:4183-8.
34. Dryden MS, Dailly S, Crouch M. A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J Hosp Infect 2004; 56:283-6.
35. Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007;44:178- 85.
36. Ellis MW, Griffith ME, Dooley DP, et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin- resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother 2007; 51: 3591-8.
37. Mertz D, Frei R, Jaussi B, et al. Throat swabs are necessary to reliably detect carriers of Staphylococcus aureus. Clin Infect Dis 2007;45:475-7.
38. Rohr U, Wilhelm M, Muhr G, Gatermann S. Qualitative and (semi)quantitative characterization of nasal and skin methicillin-resistant Staphylococcus aureus carriage of hospitalized patients. Int J Hyg Environ Health 2004;207:51-5.
39. Jones JC, Rogers TJ, Brookmeyer P, et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 2007;45:541-7.
40. van Rijen MM, Bonten M, Wenzel RP, Kluytmans JA. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review. J Antimicrob Chemother 2008;61:254- 61.
41. Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008; 148:409-18.